RxDoctor Payments DataLook up a doctor →

Paul Winner, DO

Neurology with Special Qualifications in Child Neurology · West Palm Beach, FLNPI 1831201243

Payments from drug & device makers

$18,396,062in general payments, 2019–2025

Across 1,992 payments — averaging $9234.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$9.7M
  • Novartis$2.8M
  • E.r. Squibb & Sons, L.L.C.$1.3M
  • Janssen Research & Development, LLC$777K
  • AbbVie$637K
  • Amgen$495K
  • plus $2.7M from 54 others
$75,523in research payments, 2019–2025

Across 24 payments — averaging $3146.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$55K
  • Pfizer$19K
  • Sanofi US Services Inc.$820
  • Novartis$675

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly78$9,679,393
Novartis100$2,791,563
E.r. Squibb & Sons, L.L.C.11$1,340,165
Janssen Research & Development, LLC115$777,397
AbbVie(2 entities)288$637,149
Amgen154$495,353
Eisai Inc.54$488,188
Sanofi67$457,165
H. Lundbeck A S72$388,607
Teva Pharmaceuticals USA, Inc.213$304,202
Lilly USA, LLC205$183,899
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)67$160,377
Biogen57$146,399
Biohaven Pharmaceutical Holding Company Ltd.16$78,257
UCB SA5$75,265
Biohaven Pharmaceuticals, Inc.19$73,729
Supernus Pharmaceuticals, Inc.30$62,231
Genentech, Inc.2$52,845
Lundbeck LLC73$46,246
Pfizer20$34,336
EMD Serono, Inc.53$33,652
Merz Pharmaceuticals, LLC4$31,700
Novo Nordisk AS19$25,529
Axsome Therapeutics, Inc.8$11,919
Biodelivery Sciences International, Inc.3$6,600
Impel Pharmaceuticals Inc.4$3,931
Tonix Medicines, Inc.2$1,314
UCB, Inc.38$1,000
Ares Trading SA11$935
Collegium Pharmaceutical, Inc.1$900
MDD US Operations, LLC6$820
Acadia Pharmaceuticals Inc16$648
Neurelis, Inc.24$534
Otsuka America Pharmaceutical, Inc.14$462
Upsher-smith Laboratories LLC21$352
Genentech USA, Inc.11$320
AstraZeneca5$310
Mallinckrodt Hospital Products Inc.11$299
Scilex Pharmaceuticals Inc.15$281
Bristol Myers Squibb10$258
Almatica Pharma LLC8$201
Catalyst Pharmaceuticals, Inc.8$155
Jazz Pharmaceuticals Inc.3$148
SK Life Science, Inc.5$125
TG Therapeutics, Inc.1$106
Adamas Pharmaceuticals, Inc.7$101
Argenx US, Inc.4$87
Kyowa Kirin, Inc.4$72
Bausch Health US, LLC3$54
Avion Pharmaceuticals3$53
Assertio Therapeutics, Inc.2$44
Vanda Pharmaceuticals Inc.2$37
Johnson & Johnson2$34
Currax Pharmaceuticals LLC2$29
Neurocrine Biosciences, Inc.2$29
C2n Diagnostics, LLC2$29
Takeda Pharmaceuticals U.S.A., Inc.1$26
Livanova USA, Inc.1$25
Vertical Pharmaceuticals, LLC1$24
Alnylam Pharmaceuticals Inc.1$22

How this compares

$18,396,062 in reported general payments places this provider in the 95th percentile of 137 neurology with special qualifications in child neurology providers in Florida.

See all neurology with special qualifications in child neurology providers in Florida →

Medicare billing

Part B allowed, 2024
$94,801
Medicare patients
121
Services billed
4,670

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology with special qualifications in child neurology in West Palm Beach

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →